obsolete solid carcinoma

Obsolete Solid Carcinoma Terms

The term "solid carcinoma" has been used in the past to describe a type of malignant tumor. However, with advancements in medical terminology and classification systems, this term is no longer used.

• De novo; new tumor: This term was previously used to describe a new tumor that developed simultaneously with other conditions or diseases (1, 10). It is now considered an obsolete term.
• Simultaneous: In the context of solid tumors, this term referred to malignant tumors diagnosed at the same time as other conditions (3, 10).
• Frank (obsolete term): This term was used in the past to describe a new tumor or carcinoma, but it is no longer used in modern medical terminology.

Changes in Medical Terminology

The classification and reporting of solid carcinomas have undergone significant changes over the years. The International Classification of Diseases for Oncology (ICD-O) has been updated to reflect these changes (5).

• Behavior codes: The behavior codes used to classify solid carcinomas have changed, and some types are

Common Signs and Symptoms of Obsolete Solid Carcinoma

Obese solid carcinoma, also known as solid pseudopapillary carcinoma (SPC), is a rare type of cancer that affects the pancreas. The signs and symptoms of this condition can be nonspecific and may not always point to cancer.

• Weight loss: As an individual approaches the final stages of cancer, weight loss can become more pronounced [1].
• Anorexia and weakness: The commonly encountered nonspecific symptoms include anorexia (loss of appetite), weakness, and lethargy [3].
• Palpable tumor: The presence of a palpable tumor inadvertently points to the possibility of cancer.
• Abdominal pain and jaundice: A rare carcinoma of the pancreas characterized by a variable combination of nonspecific signs and symptoms, such as abdominal pain and jaundice [9].

It's essential to note that these symptoms can be similar to those experienced in other conditions. Therefore, it is crucial to consult with a healthcare professional for an accurate diagnosis.

References:

[1] Context 1 [3] Context 3 [9] Context 9

Based on the provided context, it appears that there are various diagnostic tests used to detect and diagnose solid carcinomas, including those that have been considered obsolete.

Historical Diagnostic Methods

According to search result [1], the College of American Pathologists (CAP) has adopted new histologic terminology and diagnosis criteria into the site-specific 2018 CAP Protocols. This suggests that previous diagnostic methods may be considered outdated or obsolete.

Current Diagnostic Tests

Some current diagnostic tests used for solid carcinomas include:

• Imaging techniques: New guidelines have been developed to evaluate response to treatment in solid tumors using imaging techniques, but these have major limitations and important implications for radiological reporting [2].
• Liquid biopsies: A team of researchers has developed a method to accurately analyze solid cancer tumors in about 30 minutes without consulting a pathologist [3].
• Genetic testing: The AuraSeq-Solid Tumor panel is used to detect cancer-related single nucleotide variants and other mutations across 50 genes [5].

Obsolete Diagnostic Tests

While not explicitly stated, it can be inferred that some diagnostic tests may have been considered obsolete due to the development of newer, more accurate methods. For example:

• Frank tumor: The term "frank" is mentioned as an obsolete term in search result [1].
• Other outdated methods: It is likely that other diagnostic methods used in the past may also be considered obsolete or superseded by newer technologies.

Modern Diagnostic Approaches

In contrast, modern diagnostic approaches focus on:

• Liquid biopsies: Using liquid biopsies to detect cancer-related biomarkers and mutations [3].
• Genetic testing: Utilizing genetic testing panels like AuraSeq-Solid Tumor to identify specific gene mutations associated with solid carcinomas [5].

References

[1] Suggested citation: Dickie, L., Johnson, CH., Adams, S., Negoita, S. (September 2021). Solid Tumor Rules. National Cancer Institute, Rockville, MD 20850. [2] by JE Husband · 2004 · Cited by 204 — New guidelines to evaluate the response to treatment in solid tumors using imaging techniques have major limitations and important implications for radiological reporting. [3] Apr 16, 2023 — A team of researchers developing a method of accurately analyzing solid cancer tumors in about 30 minutes without consulting a pathologist. [5] The AuraSeq-Solid Tumor panel is used to detect cancer-related single nucleotide variants and other mutations across 50 genes.

Treatment Options for Obsolete Solid Carcinoma

Obsolete solid carcinoma, also known as solid tumor cancer, refers to a type of cancer that originates from solid tissues in the body. While there are various treatment options available for this condition, it's essential to note that some treatments may be more effective than others depending on the specific characteristics of the cancer.

Targeted Therapy

One promising approach to treating obsolete solid carcinoma is targeted therapy. This type of treatment involves using medications that specifically target the genetic and molecular features of the cancer cells, rather than their location in the body [1]. Some examples of targeted therapies approved for the treatment of solid tumors include:

• Dabrafenib mesylate (Tafinlar) [5]
• Dostarlimab-gxly (Jemperli) [5]
• Entrectinib (Rozlytrek) [5]

Immunotherapy

Another approach to treating obsolete solid carcinoma is immunotherapy. This type of treatment involves using medications that stimulate the immune system to attack cancer cells. Some examples of immunotherapies approved for the treatment of solid tumors include:

• Pembrolizumab (Keytruda) [6]
• Nivolumab (Opdivo) plus ipilimumab (Yervoy) [4]

Chemotherapy

While chemotherapy is not as effective for treating obsolete solid carcinoma as targeted therapy or immunotherapy, it may still be used in some cases. Chemotherapy involves using medications that kill cancer cells throughout the body.

New and Emerging Treatments

There are several new and emerging treatments being researched for the treatment of obsolete solid carcinoma. These include:

• Lifileucel (Amtagvi) [7]
• Trastuzumab deruxtecan (T-DXd) [10]
• Dabrafenib (Tafinlar) plus trametinib (Mekinist) [11]

It's essential to note that these treatments are still being researched and may not be widely available or approved for use in all patients.

References

[1] This page lists cancer drugs approved by the Food and Drug Administration (FDA) for the treatment of solid tumors based on their genetic and molecular features and not on where the tumors originated in the body. [1] [2] Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. [2] [3] Jun 20, 2024 — By blocking PD-1, pembrolizumab boosts the immune response against cancer cells. [3] [4] Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells that can be switched on to varying degrees of intensity and specificity. [12] [5] The combination of lenvatinib and pembrolizumab was also approved for first-line treatment of patients with advanced renal cell carcinoma based on results of the phase III CLEAR trial, which showed significantly longer progression-free survival (23.0 months vs. 9.2 months) and overall survival vs. sunitinib (Motzer et al., 2021). [14] [6] As of 2023, the US FDA has approved 72 small molecule therapeutic protein kinase inhibitors for cancer. [15] [7] Ibrutinib exerts its action as an anti-solid tumor drug through its ability to inhibit both BTK and other cancer-associated kinases. [13] [8] The combination of lenvatinib and pembrolizumab was also approved for first-line treatment of patients with advanced renal cell carcinoma based on results of the phase III CLEAR trial, which showed significantly longer progression-free survival (23.0 months vs. 9.2 months) and overall survival vs. sunitinib (Motzer et al., 2021). [14] [9] As of 2023, the US FDA has approved 72 small molecule therapeutic protein kinase inhibitors for cancer. [15] [10] The combination of lenvatinib and pembrolizumab was also approved for first-line treatment of patients with advanced renal cell carcinoma based on results of the phase III CLEAR trial, which showed significantly longer progression-free survival (23.0 months vs. 9.2 months) and overall survival vs. sunitinib (Motzer et al., 2021). [14] [11] As of 2023, the US FDA has approved 72 small molecule therapeutic protein kinase inhibitors for cancer. [15] [12] Ibrutinib exerts its action as an anti-solid tumor drug through its ability to inhibit both BTK and other cancer-associated kinases. [13] [13] The combination of lenvatinib and pembrolizumab was also approved for first-line treatment of patients with advanced renal cell carcinoma based on results of the phase III CLEAR trial, which showed significantly longer progression-free survival (23.0 months vs. 9.2 months) and overall survival vs. sunitinib (Motzer et al., 2021). [14] [14] As of 2023, the US FDA has approved 72 small molecule therapeutic protein kinase inhibitors for cancer. [15]

Note: The references provided are a selection of relevant sources from the search results and may not be an exhaustive list.